Remix Therapeutics
The Senior Manager, SEC Reporting will support public company readiness initiatives and lead external financial reporting activities for a clinical‑stage biotechnology company. Reporting to the Head of Finance, the role involves preparing SEC filings, handling technical accounting matters, and establishing scalable reporting and compliance processes.
Headquarters
Watertown, Massachusetts, United States
Company Size
51-200 employees
Founded
2018
Remix Therapeutics is a clinical-stage biotechnology company developing small molecule therapies that modulate RNA processing to address disease drivers. The company's proprietary REMaster™ platform designs small molecules that harness cellular machineries to control RNA processing and modulate expression of disease-driving mRNAs and proteins, including historically undruggable targets. Its lead program, REM-422, is a first-in-class orally available small molecule mRNA degrader targeting MYB, with programs spanning oncology and other indications of high unmet medical need.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Remix Therapeutics.
28% above the average for this role
Remix Therapeutics names Mythili Koneru as chief medical officer By Investing.com
Jan 6, 2026
Senior Manager, SEC Reporting
P.F. Chang's China Bistro, Inc.
Associate Director, SEC Reporting & Technical Accounting
Avalyn Pharma
Technical Accounting and SEC Reporting Lead
CompoSecure
Senior SEC Reporting Analyst
Orion180
Director of SEC Reporting and Technical Accounting
Transforming Hypertrophic Cardiomyopathy Care
Staff Accountant, SEC Reporting
Black Rifle Coffee Company